Screener
BridgeBio Pharma BBIO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
| Net loss | (166,555) | (169,608) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,512 | 2,186 |
| Net loss attributable to common stockholders of BridgeBio | $(164,043) | $(167,422) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.84) | $(0.88) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted | 194,789,897 | 190,145,253 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's EPS (diluted)?
- BridgeBio Pharma (BBIO) reported EPS (diluted) of -$0.84 in Q1 2026.
- How has BridgeBio Pharma's EPS (diluted) changed year-over-year?
- BridgeBio Pharma's EPS (diluted) increased by 4.5% year-over-year, from -$0.88 to -$0.84.
- What is the long-term trend for BridgeBio Pharma's EPS (diluted)?
- Over 4 years (2021 to 2025), BridgeBio Pharma's EPS (diluted) has grown at a -1.0% compound annual growth rate (CAGR), from -$3.92 to -$3.77.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about BridgeBio Pharma's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude